Objective-Arterial calcification is associated with cardiovascular disease as a complication of advanced atherosclerosis.
A therosclerotic vascular damage associated with aging manifests several features, namely atherosis, sclerosis, and calcific change, finally leading to cardiovascular events. These pathological changes result in arterial wall thickening (localized morphological changes) and arterial stiffening (functional changes). 1 Arterial calcification makes the management of hemodynamics more difficult in the elderly, because ectopic calcium deposition in the aorta and arteries contributes to vessel wall stiffening and loss of elastic recoil. 2 These pathological conditions result in unstable hemodynamic consequences, finally leading to a decline in end-organ perfusion and subsequent ischemic events. Recently, several reports have demonstrated that aortic calcification detectable on chest X-ray examination is a strong predictor of future cardiovascular events beyond traditional risk factors. 3 Arterial calcification is anatomically separated into two types, intimal and medial calcification. 4 Intimal calcification, which is seen as patchy scattered deposits only occurring within atherosclerotic plaques, is shown to be associated with plaque vulnerability. 5 On the other hand, medial calcification, which is frequently seen in the elderly and in diabetes and chronic renal failure, is observed as continuous linear deposits along the internal elastic lamina. 6 Advanced atherosclerosis with both types of calcified lesions is the consequence of overlapping pathological mechanisms.
Ectopic calcification in the vasculature has been shown to result from passive precipitation of calcium with aging and osteoporosis, the so-called calcium shift theory, as a previous hypothesis. 7 However, accumulating recent evidence has shown it to be attributable to an active "cell-mediated process" resembling osteogenesis in bone rather than passive mineral precipitation in vascular smooth muscle cells (SMCs). 8, 9 Silent information regulator-2 (Sir2), an NAD ϩ -dependent HDAC, is highly conserved in organisms ranging from Archaea to humans. 10 In yeast, Sir2 has been shown to play critical roles in DNA repair, stress resistance, and longevity. Mammalian sirtuin 1 (SIRT1), the closest homolog of Sir2, regulates the cell cycle, apoptosis, and metabolism by interacting with a number of molecules, including p53, promyelocytic leukemia protein, Foxo, Ku70, and peroxisome proliferator-activated receptor-␥. 11 A previous study has shown that SIRT1 antagonizes p53mediated premature senescence in mouse embryo fibroblasts. 12 In addition, we have recently demonstrated that SIRT1 inhibits oxidative stress-induced premature senescence in vascular endothelial cells. 13 However, the detailed mechanism of how SIRT1 affects vascular SMC senescence and arterial calcification remains unclear.
In this study, we hypothesized that SIRT1 plays an important role in preventing arterial calcification due to renal failure, in association with modulation of cellular senescence. Here, we demonstrated the protective potential of SIRT1 against hyperphosphatemia-induced premature and replicative senescence and subsequent calcification in SMCs.
Methods

Aortic Calcification in Renal Failure Rats
Renal failure was induced in rats by a 0.75% adenine-containing diet as previously described. 14 All procedures and animal care were in accordance with the Guide for the Care and Use of Laboratory Animals of the University of Tokyo. Detailed methods are described in the supplemental materials, available online at http://atvb.ahajournals.org.
Induction of SMC Calcification
Primary human aortic SMCs (HASMCs) were treated with a pathological concentration of inorganic phosphate (Pi) up to 3.2 mmol/L in culture medium as previously described. 29 To quantitatively measure Pi-induced calcification, two distinct experiments were performed as previously described 14 : (1) intracellular calcium deposition as determined by o-cresolphthalein complexone method, and (2) visualization of mineralization as determined by von Kossa staining, Detailed methods are described in the supplemental materials.
Senescence-Associated ␤-Galactosidase Staining
To assess senescent changes in the phenotype of cultured HASMCs or aortic medial cells of rats, staining for senescence-associated ␤-galactosidase (SA␤-gal), a well-established biomarker of cellular senescence, was performed. Detailed methods are described in the supplemental materials.
Knockdown of SIRT1 or p21 by Small Interfering RNA
HASMCs were transfected with 200 pmol/L small interfering RNA (siRNA) for SIRT1, p21 WAF1/CIP1 , or both. Detailed methods are described in the supplemental materials.
Real-Time Polymerase Chain Reaction Analysis: Osteoblastic Markers
To examine whether Pi stimulation induces change to an osteoblastic phenotype, the expression of Runx-2/Cbfa-1 and alkaline phosphatase, which are well known to be representative osteoblastic markers, was checked using real time-polymerase chain reaction analysis. In addition, the effect of knockdown of SIRT1, p21, or both by siRNA on the osteoblastic phenotypic change in HASMCs was examined. Primer sequences are shown in Supplemental Figure I.
Results
Association of Senescent Vascular Cells With Aortic Medial Calcification in Renal Failure Rats
The adenine-fed rats had severe renal failure, with a huge increase in serum creatinine (3.0Ϯ0.9 mg/dL in renal failure rats versus 0.3Ϯ0.0 mg/dL in control rats), similar to a previous report. 14 The renal failure rats showed an approximately 2.0-fold increase in serum phosphorus (18.9Ϯ4.7 mg/dL) compared with control rats (9.8Ϯ0.9 mg/dL). Histological assessment using von Kossa staining showed that the aorta in renal failure rats had extensive linear calcification, which was localized in the aortic media, resembling the typical Mönckeberg's pattern ( Figure 1A ). Numerous SA␤-gal positive cells were found in the aortic media of renal failure rats, whereas the aortic wall in control rats did not contain senescent cells ( Figure 1B ). The senescent cells were mainly localized to the calcified area and its surrounding area, which was defined as the area not stained black by von Kossa staining. Quantitative assessment showed that the number of senescent cells with high SA␤-gal activity was positively correlated with the calcified area in the aortic media ( Figure 1C ).
Pi Induces Cellular Senescence in Cultured SMCs
On the basis of our results obtained from animal experiments, we hypothesized that senescent SMCs in the aortic media are strongly associated with the development of arterial calcification. Therefore, the effect of excessive Pi stimulation (2.6 mmol/L) on cellular senescence in cultured SMCs was examined. SA␤-gal-positive senescent HASMCs were significantly induced by not only angiotensin II (Ang II) but also Pi stimulation (Figure 2A ). Notably, Pi stimulation increased calcium deposition; however, Ang II alone did not ( Figure  2B ). It suggests that high-dose Pi condition, but not stress by Ang II alone, is indispensable to induce SMC calcification.
These findings also suggest that intracellular Pi influx at least is essential to induce this SMC calcification model.
In addition, to determine how many days after the initiation of Pi stimulation the cells showed a senescent phenotype and subsequent calcification, the time-dependent effects of Pi stimulation on both SA␤-gal activity and calcium deposition were examined. As shown in Figure 2C , SA␤-gal-positive cells were significantly increased by Pi stimulation even on day 1, although calcium deposition was not markedly increased at the same time point. A statistically significant increase in calcium deposition was found from day 3 and later. Cotreatment with phosphonoformic acid, an inhibitor of Na-dependent phosphate cotransporter (NPC), showed significant inhibition of Pi-induced senescence ( Figure 2D ). Our previous report showed that treatment with PFA completely inhibited Pi-induced SMC calcification, 15 suggesting the importance of increased intracellular influx of phosphate in Pi-induced SMC senescence.
Downregulation of SIRT1 by Pi
Treatment of HASMCs with Pi caused downregulation of SIRT1 expression in a time-dependent manner ( Figure 3A ). The decline was dependent on Pi concentration (data not shown). An increase in acetylation of both substrates of SIRT1, histone-3 and p53 (a nonhistone substrate), was found according to the decline in SIRT1 deacetylase activity. In addition, expression of p21, a downstream molecule of p53, was significantly induced by Pi as well. Quantitative assessment showed that an increase in these expression levels of acetylated (Ac)-p53 and p21 on day 3 and day 6 was statistically significant compared with the pretreatment levels, suggesting that downregulation of SIRT1 activity may mediate the subsequent increase in Ac-p53 and p21 expression.
To address whether SIRT1 downregulation-related SMC senescence and calcification are reversible or not, the effects of continuation or termination of high-dose Pi were examined. As shown in Figure 3B , the continuation of Pi up to day 10 was associated with SIRT1 downregulation and subsequent upregulation of Ac-p53 and p21, leading to induction of senescence-related calcification. However, the slight increase in senescent cells was not statistically significant, although calcification was significantly induced. Of note, the Pi-induced downregulation of SIRT1 was almost completely reversed by withdrawal (termination) of Pi stimulation (exchange of Pi from 2.6 mmol/L to 1.4 mmol/L as a normal level on day 6) as shown in Figure  3B . According to the restoration of SIRT1, levels of both Ac-p53 and p21 were also decreased without more progression. In addition, termination of Pi showed no progression of senescence-related calcification; however, preexisting senescent cells and calcification on day 6 continued without regression.
Next, NPC inhibition by PFA completely blunted Piinduced SIRT1 downregulation and subsequent activation of its downstream p53/p21 pathway ( Figure 3C ).
Regulation of SIRT1 Modulates Pi-Induced SMC Senescence and Calcification
The effects of modulation of SIRT1 activity on Pi-induced cellular senescence were investigated. First, sirtinol, a chem- Representative photographs showed that senescence-associated ␤-galactosidase (SA␤-gal) activity (blue) in cells was significantly induced by not only angiotensin II (Ang II: 10 pmol/L, as a positive control) but also Pi stimulation (2.6 mmol/L). B, The number of senescent cells was significantly increased by not only Ang II but also Pi. Calcium deposition was significantly increased by Pi; however, calcification in HASMCs was not induced by Ang II alone in the absence of Pi. C, Senescent cells were significantly increased by Pi stimulation even on day 1; however, a statistically significant increase in calcium deposition was found from day 3 and later. D, Inhibition of the phosphate cotransporter Na-dependent phosphate cotransporter by the inhibitor phosphonoformic acid (PFA) (100 mol/L) reduced SA␤-gal activity, which was increased by Pi (2.6 mmol/L) in HASMCs. Each experiment was performed al least 3 times.
ical inhibitor of SIRT1, induced an increase in SA␤-galpositive cells even under a normal Pi (1.4 mmol/L), and the increased number of senescent cells induced by Pi was significantly augmented by sirtinol ( Figure 4A ). Sirtinol dose-dependently augmented Pi-induced calcification, although no augmentation was found under a normal Pi ( Figure  4B and 4C). Conversely, treatment with resveratrol, an activator of SIRT1, significantly reduced both Pi-induced senescent transition and calcification in a dose-dependent manner ( Figure 4D to 4F).
Second, complete knockdown of SIRT1 by siRNA caused a significant increase in acetylation of both substrates (histone-3 and p53) and p21 expression ( Figure 5A ). Similarly to sirtinol, SIRT1 inhibition by siRNA also augmented not only senescent transition ( Figure 5A , bottom) but also calcium deposition ( Figure 5C , top).
Although stimulation with Ang II alone could increase the number of SA␤-gal-positive cells, it did not increase calcium deposition. To understand the mechanism of these discrepant phenomena, the effect of Ang II alone on osteoblastic phenotypic change was examined. Ang II alone did not increase the expression of Runx2 in the absence of Pi stimulation, unlike Pi stimulation ( Figure 5B ).
To understand the detailed mechanism by which SIRT1 modulates senescence-related calcification, the effect of SIRT1 on phenotypic change in HASMCs was examined. Pi inhibited the expression of caldesmon, a differentiated SMC lineage marker, and complete knockdown of SIRT1 augmented the Pi-induced partial downregulation of caldesmon ( Figure 5C , middle). In contrast, real-time polymerase chain reaction analysis showed that Pi induced the expression of two representative osteoblastic markers, Runx-2/Cbfa-1 and alkaline phosphatase ( Figure 5C , bottom) with statistical significance. In addition, complete knockdown of SIRT1 using siRNA significantly accelerated the Pi-induced os- showed downregulation of SIRT1 expression, leading to an increase in acetylation of its substrates (acetylated [Ac]-H3 and Ac-p53) and p21 expression. Bottom: Quantitative analysis showed that Pi gradually induced not only SIRT1 downregulation but also upregulation of Ac-p53 and p21. B, To address whether SIRT1 downregulation-related senescence and subsequent calcification are reversible, the effects of continuation or termination of high-dose Pi were examined. As shown in 4th lane from left, termination (on day 6) of Pi showed no progression of senescence-related calcification in association with restoration of SIRT1, whereas continuation (up to day 10, 3rd lane from left) of Pi stimulation showed further progression of calcification. C, Treatment with phosphonoformic acid (PFA), a Na-dependent phosphate cotransporter inhibitor, completely reversed Pi-induced SIRT1 downregulation. A decline in Ac-H3 and Ac-p53 reflected the restoration of SIRT1 deacetylase activity. Pi-induced p21 activation was significantly inhibited by inhibition of Pi transport.
teoblastic phenotypic change, suggesting that modulation of SIRT1 is associated with osteoblastic phenotypic change in SMCs.
Inhibition of Senescence-Related Calcification in SMCs by p21 Knockdown
To address the association of p21 with senescence-related calcification, knockdown of p21 using siRNA was performed. Treatment of p21 siRNA (up to 200 pmol/L) completely inhibited p21 ( Figure 5D ). p21 knockdown completely inhibited Pi-induced senescence and subsequent calcification ( Figure 5E ).
Regulation of NPC-Mediated Runx2 Expression by SIRT1/p21 Pathway
As the next step, the role of SIRT1 in NPC-mediated Runx2/Cbfa1 expression was examined. First, complete knockdown of SIRT1 did not show any change in both osteoblastic markers, Runx2 and alkaline phosphatase, in a normal Pi (Supplemental Figure I) . As shown in Figure 5F , Pi-induced Runx2 was significantly blunted by PFA, an NPC inhibitor. SIRT1 activation by resveratrol inhibited Piinduced Runx2 activation. The Runx2 induction was augmented by knockdown of SIRT1 by siRNA, and the activation was completely inhibited by PFA. Surprisingly, Runx2 activation was strongly inhibited by knockdown of p21 alone. In addition, the inhibition of Runx2 induction by double knockdown of SIRT1 and p21 was less than that by single knockdown of SIRT1.
To address a difference in senescent induction by Pi or Ang II, immunohistological assessment of SIRT1 in HASMCs was examined (Supplemental Figure II) . Although SIRT1 was predominantly localized in nucleus without Pi, the translocation of SIRT1 to cytoplasm was observed after Pi stimulation for 24 hours, and its expression disappeared in both areas on day 6. In contrast, Ang II stimulation did not show the dynamic translocation.
High Sensitivity of SMCs With Replicative Senescence to Pi-Induced Calcification
Not only Pi-induced "premature senescence" in HASMCs but also the effects of Pi on "replicative senescence" were evaluated. Senescent cells (passage 18) were more sensitive to Pi-induced calcification compared with young cells (passage 7) ( Figure 6A ). SIRT1 expression was downregulated in senescent cells compared with young cells, and the downregulation was significantly augmented by Pi stimulation (Figure 6B, top) . In parallel with this finding, senescent cells showed an increase in Ac-p53 and p21 expression. Statistical analyses using densitometric measurement showed that (1) downregulation of SIRT1 and upregulation of Ac-53 and p21 were augmented by replicative senescence, and (2) Pi inhibited the SIRT1-p21 pathway even in cells with replicative senescence (passage 18) ( Figure 6B , bottom).
Discussion
Vascular aging, leading to cardiovascular disease, manifests complex and diverse vascular changes (eg, impairment of distensibility due to loss of arterial elasticity). 1, 16 Arterial wall stiffness resulting from ectopic calcification is a complication of advanced atherosclerosis and makes the management of hemodynamics more difficult in the elderly. Few reports have addressed whether cellular senescence is associated with SMC calcification. This study showed the importance of SIRT1, a longevity gene, in arterial calcification in association with cellular senescence.
First, our data obtained from animal experiments clearly showed the association of senescent SMCs with aortic medial calcification in the renal failure rats with hyperphosphatemia. Senescent cells showed significant colocalization with calcium deposition. Intriguingly, numerous senescent cells could be detected before microscopic calcification occurred at 4 weeks after the start of renal failure induction (data not shown), suggesting that the transition to a senescent phenotype in medial SMCs may be associated with the initiation and progression of calcification. Therefore, hyperphosphatemia, a potent uremic factor, may be a stimulator to induce senescent phenotypic transition of medial SMCs. Second, we also confirmed the association of Pi-induced SMC senescence with calcification in in vitro experiments. Senescent SMCs were significantly increased by Pi even on day 1, although calcium deposition was not markedly increased at the same time point. A statistically significant increase in calcium deposition was found from day 3 and later. Considering these data, we hypothesize that (1) calcium deposition may be more readily induced in senescent cells compared with nonsenescent cells, and (2) Pi-induced senescent change is observed earlier than calcium deposition. In other words, senescent transition associated with Runx2 induction may lead to progressive calcification.
Senescent SMCs were associated with the SIRT1-related p53/p21 pathway, based on the findings that SIRT1 knockdown augmented not only cellular senescence but also calcification. In addition, p21 knockdown completely inhibited senescencerelated calcification induced by Pi. This raises the question of how cellular senescence in SMCs is associated with calcification. Our experiments to understand the detailed mechanisms by which SIRT1 modulates senescence-related calcification showed that Pi-induced SIRT1 downregulation led to the phenotypic change from a differentiated state to osteoblast-like cells in SMCs. It has been reported that Pi induces osteoblastic change, in which NPC plays a role in inducing Runx2/Cbfa-1 expression, in SMCs. 17 As the next step, to determine how SIRT1 regulates NPC-mediated Runx2 expression, we examined the effects of knockdown of SIRT1, p21, or both by siRNA on Pi-induced Runx2 expression. Our data shown in Figure 5F suggested that (1) NPC plays an essential role in Pi-induced Runx2 expression, (2) SIRT1 has an inhibitory effect on NPCmediated Runx2 expression, (3) knockdown of p21 alone ameliorates Runx2 induction, and (4) p21-related osteoblastic change is at least in part dependent on SIRT1.
There is now the new question of how SIRT1 regulates Runx2 regulation. A report by Jeon 18 has shown that acetylation of Runx2 itself is important in osteoblast differentiation, and it is downregulated by HDAC activities. Based on this evidence, SIRT1, 1 of the HDACs, may be able to deacetylate Runx2, leading to inhibition of Runx2-related osteoblastic transition in SMCs. Therefore, the inhibition of SIRT1 by hyperphosphatemia may lead to Runx2 activation via its hyperacetylation. Further investigation of the detailed mechanism of the SIRT1/p21/osteoblastic gene axis is needed. These data clearly suggest that SIRT1 activation may inhibit the hyperphosphatemia-induced osteoblastic phenotypic change of SMCs, and the degree of change may be dependent on SIRT1 expression level. It is possible that the inhibition of SIRT1 expression by Pi alone is "partial," because complete downregulation of SIRT1 by siRNA worsened the dynamic phenotypic change compared with Pi only. We have already shown that tumor necrosis factor-␣, a potent atherogenic cytokine, augmented Pi-induced SMC calcification, as previously described. 19 In addition, tumor necrosis factor-␣ significantly decreased Pi-induced SIRT1 downregulation further (data not shown). According to these results, we currently hypothesize that hyperphosphatemia induces SIRT1 downregulation and subsequent osteoblastic phenotypic change in SMCs, leading to calcification, and these changes are worsened by some harmful atherogenic factors, which decrease SIRT1 expression/activity further. These results provide a new insight, showing that SIRT1 plays an essential role in the prevention of arterial calcification and that the beneficial effect may be associated with an inhibition in Pi-induced SMC senescent transition. In addition, Ang II did not increase calcium deposition, although the stimulation increased the number of senescent cells. Of note, Ang II alone did not increase Runx2 expression in the absence of Pi ( Figure 5B ). This result suggests that SMC senescence shows two different features: one is SA␤gal-positive cells with an increase in Runx2 and the other is SA␤-gal-positive cells without. First, it has recently been reported that SMCs with replicative senescence, rather than the cells without senescence, show hypersensitivity in response to induction of calcification with the more induction of osteoblastic markers, 20 suggesting that the induction of osteoblastic transdifferentiation is strongly associated with the senescent change in SMCs. In addition, the translocation of SIRT1 to cytoplasm was observed after Pi stimulation for 24 hours, although SIRT1 predominantly localized in nucleus without Pi. In contrast, Ang II did not show the dynamic translocation. Thinking about the mechanism for regulating the activity of HDACs, including SIRT1, recent several reports show the importance of their coordinated shuttling between nucleus and cytoplasm. A report demonstrates that HDAC7, an HDAC, represses the transcriptional activity of Runx2 and that osteogenic stimuli induce export of HDAC7 from nucleus, leading to a decline in the repressive potentials of HDAC7 for Runx2. 21 On the basis of our findings and a previous report, the reason that stimulation with Ang II alone did not induce Runx2 expression and subsequently SMC calcification may in part depend on the difference of SIRT1 translocation after stimulation. Therefore, we strongly hypothesize that in the senescent SMCs with upregulation of p21, Pi stimulation, but not Ang II stimulation, may activate Runx2 via at least two phenomena, the hyperacetylation of Runx2 by SIRT1 downregulation and the dynamic SIRT1 translocation, leading to marked osteoblastic transdifferentiation and subsequent calcification. In addition, we have another hypothesis. In general, it has been shown that high-dose Pi navigates release of matrix vesicles from SMCs in parallel with osteoblastic transdifferentiation. The vesicles play an essential role in the initiation of hydroxyapatite aggregation, so-called nucleation. Accumulating recent reports show that the nanocrystal formation as an initial step under hyperphosphatemia accelerates the harmful cascade of osteoblastic transdifferentiation in SMCs via endocytosis. 22, 23 Maybe Ang II alone does not induce the nanocrystal formation and the cascade of osteoblastic change. Therefore, we explain that the difference of senescent phenotypic changes in SMCs between both stimulations, Pi and Ang II alone, may depend on (1) SIRT1 translocation and (2) nanocrystal formation to accelerate calcification. Further investigation to address the detailed mechanisms by which SIRT1 regulates osteoblastic transdifferentiation in SMCs under the cellular senescence is needed.
Are SIRT1 downregulation-related SMC senescence and subsequent calcification reversible or not? To answer this question, the effects of continuation or termination of highdose Pi were examined. As shown in Figure 3B , termination (on day 6) of Pi showed no progression of senescence-related calcification in association with the restoration of SIRT1, whereas continuation (up to day 10) of Pi stimulation showed further progression of calcification. It is suggested that a therapeutic strategy to manage hyperphosphatemia to the normal range of serum phosphate concentration may lead to at least termination of progressive calcification via reversal of SIRT1 activity.
Cellular senescence has been shown to have two features: not only stress-induced premature senescence but also replicative senescence, indicating a limited number of divisions in culture. 24 In fact, both endothelial cells and SMCs derived from human atherosclerotic plaques show a senescent phenotype earlier than do cells from normal vessels. 25 Notably, we found that senescent HASMCs were significantly more sensitive to Pi-induced calcification compared with young cells. These results suggest that calcium deposition may be more readily induced in arterial medial SMCs with replicative senescence. This insight may explain the mechanisms by which arterial calcification occurs in the elderly more frequently than in the young population. Therefore, these observations support our hypothesis that arterial calcification is accelerated by both senescent types (premature and replicative senescence) in SMCs. To explore new therapeutic strategies against arterial calcification, it is essential to investigate how to maintain a higher SIRT1 level in the vasculature, leading to prevention of medial SMC senescence and which drug is capable of achieving it.
How does SIRT1 exert protective effects against SMC calcification? This study clearly showed that inhibition of SIRT1 was associated with increases in both Ac-p53 and p21 expression. These findings were significantly induced by not only replicative senescence but also Pi-induced premature senescence. SIRT1-mediated deacetylation of p53 inhibits p53-dependent transactivation of target genes, including p21. A report showed that a decline in cellular deacetylase activity increases the half-life of endogenous p53, 26 suggesting that p53 acetylation is also associated with p53 stabilization. Therefore, the increased Ac-p53 by Pi-induced SIRT1 downregulation may induce SMC senescence because of a decline in degradation of p53, leading to calcification. In addition, p53 itself can inhibit SIRT1 transcription because the SIRT1 promoter has two response elements to p53. 27 Further investigation to address how the SIRT1-p53 negative regulatory pathway is associated with SMC calcification is needed.
On the other hand, regarding p21 activation, it is reported that inhibition of p21 expression in the vasculature significantly attenuates cellular senescence, leading to prevention of atherosclerosis. 28 This evidence suggests a pivotal role of p21 in the development of atherosclerosis. p21 activation has been shown to be regulated by a pathway that is p53 dependent, p53 independent, or both. Okamoto et al have demonstrated that inhibition of HDAC by trichostatin A showed activation of p21 promoter activity by the Sp1 site even in vascular SMCs, and the induction of p21 was independent of the p53 pathway. 29 The p21 transcriptional activation in response to HDAC inhibitors was mediated by histone hyperacetylation in its promoter region. Based on these findings, Pi-induced p21 activation via SIRT1 downregulation may be in part involved in a p53-independent pathway, leading to a senescent phenotype of SMCs. Further investigation exploring which molecule activates the p21 promoter under hyperphosphatemia is needed.
Conclusion
We showed that SIRT1 exerts a protective role in hyperphosphatemia-based arterial calcification via inhibition of osteoblastic transdifferentiation, in association with crosstalk between calcification and cellular senescence. This ability of SIRT1 may orchestrate an analogous protective/ longevity paradigm even in vascular SMCs, leading to maintenance of healthy elasticity of the arterial wall. Strategies to maintain a higher level of SIRT1 activity may provide novel therapeutic opportunities for the prevention of arterial calcification.
